Ak­ili out­lines adult AD­HD da­ta for pre­scrip­tion video game; Medtech start­up to go pub­lic via SPAC

The dig­i­tal med­i­cine biotech Ak­ili In­ter­ac­tive re­vealed topline re­sults from a tri­al for its video game-like dig­i­tal ther­a­py En­deav­or­Rx, al­so known as AKL-TO1, in adults with AD­HD, with some pos­i­tive re­sults.

On Wednes­day, the biotech said the game pro­duced a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in at­ten­tion func­tion­ing from pa­tients af­ter six weeks of treat­ment com­pared to place­bo. Im­prove­ments were al­so not­ed in sev­er­al sec­ondary out­comes re­lat­ed to as­sess­ments of AD­HD-re­lat­ed symp­toms and qual­i­ty of life met­rics. Ak­ili re­port­ed no se­ri­ous side ef­fects.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER